U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07601204) titled 'Treatment of Recurrent/Metastatic Head and Neck Cancer' on May 17.
Brief Summary: This study is a Phase Ib/II study of TQB2922 injection (subcutaneous). In the Phase Ib stage, a 3+3 dose-escalation design was used to determine the RP2D and pharmacokinetic characteristics of TQB2922 injection (subcutaneous) administered once every 3 weeks in subjects with R/M HNC. The Phase II stage explored the efficacy and safety of TQB2922 (subcutaneous) as monotherapy or in combination therapy in subjects with R/M HNC.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Recurrent/Metastatic Head and Neck Cancer
Intervention:
D...